Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing
Year: 2017
Type: article
Abstract: Molecular classification of cancer has entered clinical routine to inform diagnosis, prognosis, and treatment decisions. At the same time, new tumor entities have been identified that cannot be defined histologically. For central nervous system tumors, the current World Health Organization classification explicitly demands molecular testing, e.g., for 1p/19q-codeletion or IDH mutations, to make an integrated histomolecular diagnosis. However, a plethora of sophisticated technologies is currently needed to assess different genomic and epigenomic alterations and turnaround times are in the range of weeks, which makes standardized and widespread implementation difficult and hinders timely decision making. Here, we explored the potential of a pocket-size nanopore sequencing device for multimodal and rapid molecular diagnostics of cancer. Low-pass whole genome sequencing was used to simultaneously generate copy number (CN) and methylation profiles from native tumor DNA in the same sequencing run. Single nucleotide variants in IDH1, IDH2, TP53, H3F3A, and the TERT promoter region were identified using deep amplicon sequencing. Nanopore sequencing yielded ~0.1X genome coverage within 6 h and resulting CN and epigenetic profiles correlated well with matched microarray data. Diagnostically relevant alterations, such as 1p/19q codeletion, and focal amplifications could be recapitulated. Using ad hoc random forests, we could perform supervised pan-cancer classification to distinguish gliomas, medulloblastomas, and brain metastases of different primary sites. Single nucleotide variants in IDH1, IDH2, and H3F3A were identified using deep amplicon sequencing within minutes of sequencing. Detection of TP53 and TERT promoter mutations shows that sequencing of entire genes and GC-rich regions is feasible. Nanopore sequencing allows same-day detection of structural variants, point mutations, and methylation profiling using a single device with negligible capital cost. It outperforms hybridization-based and current sequencing technologies with respect to time to diagnosis and required laboratory equipment and expertise, aiming to make precision medicine possible for every cancer patient, even in resource-restricted settings.
Source: Acta Neuropathologica
Institutions: Centre National de la Recherche Scientifique, Inserm, Sorbonne Université, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Institut du Cerveau, Université Pierre-et-Marie-Curie, Charité – Universitätsmedizin Berlin, Assistance Publique – Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Institute of Cancer Research, University Medical Center Utrecht, Université Paris Sciences et Lettres, Institut Curie
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: nanopore sequencing, brain tumors, central nervous system tumors, molecular diagnosis, copy number alterations, DNA methylation profiling, IDH mutation, 1p/19q codeletion, TP53 mutation, TERT promoter mutation, H3F3A mutation, glioma, medulloblastoma, brain metastases, pan-cancer classification, deep amplicon sequencing, low-pass sequencing, resource-limited settings, precision oncology
Open Access status: hybrid
Estimated APC paid: $4,990
OpenAlex ID: W2627277170
